Fenomena Raynaud

01Pathophysiology

Raynaud's phenomenon results from an exaggerated vasospastic response of the digital arteries, precapillary arterioles, and arteriovenous shunts in the fingers and toes. When a normal person is exposed to cold, the sympathetic nervous system triggers mild vasoconstriction to conserve core body heat. In Raynaud's, this response is dramatically amplified, causing near-complete cessation of blood flow to the digits.

At the molecular level, the key imbalance is between vasoconstrictors and vasodilators. Endothelin-1 (a potent vasoconstrictor released by endothelial cells) is elevated, while nitric oxide and prostacyclin (endothelium-derived vasodilators) are deficient. There is also upregulation and hypersensitivity of alpha-2 adrenergic receptors on vascular smooth muscle, making these vessels overreact to sympathetic stimulation.

This pathophysiology directly explains the triphasic color change. First, intense vasospasm causes complete cessation of arterial inflow, producing white (pallor). As the trapped venous blood becomes deoxygenated, the digits turn blue (cyanosis). When the spasm resolves and blood rushes back in (reactive hyperemia), the digits become red (erythema), often with throbbing pain. This white-to-blue-to-red sequence is the hallmark finding.

In secondary Raynaud's, the vasospasm occurs on top of pre-existing structural vascular damage. In scleroderma, for example, there is intimal fibrosis and adventitial fibrosis of the digital arteries, narrowing the lumen permanently. This is why secondary disease produces more severe ischemia, leading to digital ulcers, pitting scars, and even gangrene, findings that are virtually absent in the primary form.

A critical concept for the exam: Raynaud's phenomenon can be the earliest manifestation of systemic sclerosis, appearing years to decades before skin thickening or internal organ involvement develops. A vignette describing a young woman with isolated Raynaud's and a positive anticentromere antibody is testing whether you recognize early limited scleroderma (formerly CREST syndrome).

02Classification and Clinical Manifestation

Common Associations in Secondary Disease

03Diagnostic Workup

The diagnosis of Raynaud's is fundamentally clinical. The history of episodic, well-demarcated triphasic color changes (pallor, cyanosis, then rubor) of the digits provoked by cold or emotional stress is sufficient to establish the diagnosis. No single lab test "confirms" Raynaud's itself. The real diagnostic challenge, and where the exam focuses, is distinguishing primary from secondary disease.

Once you recognize Raynaud's in a vignette, the next step is to determine if an underlying cause exists. Order ANA as the initial serologic screen. A negative ANA with a normal ESR, normal nailfold capillaroscopy, and no digital ulcers strongly supports primary Raynaud's. A positive ANA triggers further workup: anticentromere antibody, anti-Scl-70, anti-U1 RNP, anti-dsDNA, complement levels, and anti-Smith, depending on clinical suspicion.

Nailfold capillaroscopy is the single most important test for distinguishing the two forms. In primary Raynaud's, the capillary loops appear normal. In secondary disease (especially scleroderma spectrum), you see enlarged, distorted capillary loops with areas of capillary dropout and microhemorrhages. This finding alone can reclassify a patient from "primary" to "early secondary" even before any other clinical signs of connective tissue disease appear.

When a vignette provides a patient with Raynaud's and asks what test to order next, the answer depends on context. If the question is about screening for an underlying cause, choose ANA. If the question is about the most accurate way to differentiate primary from secondary, choose nailfold capillaroscopy.

04Management and Treatment

For all patients, the foundation of management is non-pharmacologic. Cold avoidance is the single most effective measure: the patient should wear insulated gloves, keep the core body warm, and avoid abrupt temperature changes. Smoking cessation is essential because nicotine is a potent vasoconstrictor that worsens digital ischemia. Any medications known to exacerbate vasospasm must be discontinued, with beta-blockers being the most commonly tested offender.

When lifestyle measures are insufficient, first-line pharmacotherapy is a dihydropyridine calcium channel blocker. Nifedipine is the most studied and most frequently tested drug. It relaxes vascular smooth muscle by blocking L-type calcium channels, directly counteracting the vasospasm. Start with nifedipine extended-release 30 mg daily and titrate up to 60-90 mg daily as tolerated. Amlodipine 5-10 mg daily is an acceptable alternative with a longer half-life and better side-effect profile (less reflex tachycardia, less headache). A critical distinction: use dihydropyridine CCBs (nifedipine, amlodipine), NOT non-dihydropyridine CCBs (verapamil, diltiazem). Verapamil and diltiazem have weaker peripheral vasodilatory effects and are not standard for Raynaud's.

If CCBs fail or are not tolerated, PDE-5 inhibitors (sildenafil, tadalafil) are the next option. These drugs enhance nitric oxide-mediated vasodilation by preventing breakdown of cyclic GMP. Sildenafil 20 mg TID is a commonly used regimen. Topical nitroglycerin applied directly to affected digits is another option, though headaches and tachyphylaxis limit its use.

For severe or refractory disease with critical digital ischemia or non-healing ulcers, IV iloprost (a prostacyclin analogue) is used. It provides potent vasodilation and also inhibits platelet aggregation. In systemic sclerosis patients with recurrent digital ulcers, bosentan (an endothelin receptor antagonist) is used for ulcer prevention. Note that bosentan is hepatotoxic and requires monthly liver function monitoring, and it is teratogenic (pregnancy category X).

If all medical therapy fails and there is threatened digit loss, digital sympathectomy is the surgical option. This involves stripping the adventitia from the digital arteries to remove sympathetic nerve fibers, thereby reducing vasospasm.

For secondary Raynaud's, treatment of the underlying connective tissue disease is equally important, as controlling systemic inflammation helps reduce vascular damage.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on Raynaud's questions is by failing to distinguish primary from secondary disease when the vignette provides subtle clues. A young woman with symmetric, episodic color changes, a negative ANA, and no tissue damage is straightforward primary Raynaud's. But the exam will add one detail to shift the diagnosis: an elevated ESR, a positive ANA, skin tightening over the fingers, abnormal nailfold capillaries, or digital pitting scars. Any of these should immediately redirect your thinking to secondary Raynaud's and prompt investigation for an underlying connective tissue disease, most commonly systemic sclerosis.

Another frequent trap is the drug choice. When the question asks for pharmacotherapy, the tested answer is nifedipine (a dihydropyridine CCB). Students sometimes choose verapamil or diltiazem because they are also calcium channel blockers, but these non-dihydropyridine agents are not the standard of care for Raynaud's and would be marked wrong. Similarly, be alert for vignettes where a patient on a beta-blocker develops new or worsening Raynaud's symptoms. The "next best step" is to discontinue the beta-blocker, not to add a calcium channel blocker on top of it.

A high-yield pearl: Raynaud's phenomenon can be the presenting complaint of systemic sclerosis years before any other manifestation. If a vignette describes isolated Raynaud's with a positive anticentromere antibody, the question is testing your ability to recognize early limited cutaneous systemic sclerosis. The correct answer may be "further serologic workup" or "nailfold capillaroscopy," not simply "reassurance."

Finally, remember that the triphasic color sequence matters. The vignette may describe only two of the three phases (white and blue, for instance) and still call it Raynaud's, since many patients do not exhibit all three phases in every attack. But if the color change described is exclusively red and warm (without a pallor phase), think erythromelalgia instead.